Molecular mimicry is discussed as a possible mechanism that may contribute to the development of autoimmune diseases. It could also be involved in the differential association of the human major histocompatibility subtypes HLA-B*2705 and HLA-B*2709 with ankylosing spondylitis. These two subtypes differ only in residue 116 of the heavy chain (Asp in B*2705 and His in B*2709), but the reason for the differential disease association is not understood. Using x-ray crystallography, we show here that the viral peptide pLMP2 (RRRWRRLTV) derived from latent membrane protein 2 (residues 236–244) of Epstein-Barr virus (EBV) is presented by the B*2705 and B*2709 molecules in two drastically deviating conformations. Extensive structural similarity between pLMP2 and the self-peptide pVIPR (RRKWRRWHL) derived from vasoactive intestinal peptide type 1 receptor (residues 400–408) and is presented only when the peptides are presented by B*2705 because of a salt bridge between Arg5 of both peptides and the subtype-specific heavy chain residue Asp116. Combined with functional studies using pLMP2/pVIPR-cross-reactive cytotoxic T lymphocytes (CTLs) and clones, together with target cells presenting these peptides or a modified peptide analogue, our results reveal that a pathogen-derived peptide can exhibit major histocompatibility complex class I subtype-dependent, drastically distinct binding modes. Furthermore, the results demonstrate that molecular mimicry between pLMP2 and pVIPR in the HLA-B27 context is an allele-dependent property.

Not all HLA-B27 subtypes are equally associated with the autoimmune disease ankylosing spondylitis (AS). The frequent, prototypical subtype B*2705 is AS-associated, independent of ethnic origin, whereas B*2706 and B*2709, which exhibit geographically restricted distribution, are not (1). The products of the B*2705 and B*2709 alleles differ only in residue 116 of the HLA-B27 heavy chain (HC, Asp in B*2705 and His in B*2709) (2). This residue is located at the floor of the peptide-binding groove, forms part of the F-pocket, and is buried upon binding of a peptide. Despite the close structural similarities, the subtypes give rise to distinct repertoires of bound peptides (3) and cytotoxic T lymphocytes (CTLs) (4). B*2705-positive but not B*2709-positive individuals possess CTL that recognize the HLA-B27-bound self-peptide pVIPR (RRKWRRLWH). pVIPR is derived from vasoactive intestinal peptide type 1 receptor (residues 400–408) and is presented by B*2706 molecules in the common canonical conformation, whereas B*2705 presents the peptide in an unusual dual binding mode (5).

pVIPR exhibits sequence homology with the peptide pLMP2 (RRRWRRLTV), derived from latent membrane protein 2 (residues 236–244) of Epstein-Barr virus (EBV). The existence of CTL reacting with both peptides in the context of B*2705 suggests a relationship between infection with EBV and an expansion of the pool of pLMP2/pVIPR-cross-reactive CTL (4). However, a direct correlation between EBV infection and AS pathogenesis has not been established. Molecular mimicry (6–9) and i.e. similarity in overall shape as well as charge distribution for an interaction surface (9), has been invoked as an explanation for the association of HLA-B27 and spondyloarthropathies (10–12), but its existence has yet to be proven (13, 14). A principal difficulty is related to the fact that a host-derived epitope is expected to share antigenic but not necessarily also extensive sequence homology with a foreign antigen (15).

We have now determined the structures of both HLA-B27 subtypes in complex with pLMP2 and compare them here with the corresponding pVIPR complexes. Together with functional data, this comparison suggests that structural similarity and CTL cross-reactivity between pLMP2 and pVIPR in the context of HLA-B27 antigens are allele-dependent properties.

**EXPERIMENTAL PROCEDURES**

**HLA-B27-positive Donors, CTL Lines, and Clones—**Seven patients with AS (with the exception of one B*2707-positive individual, all typed as B*2705) and two healthy individuals (one B*2705-positive and one B*2709-positive) were enrolled for this study (see Tables III, IV, and V). HLA-B27 typing and generation of pLMP2- and pVIPR-specific CTL lines were carried out as described (4). The CTL line MP VPAC7 was cloned by limiting dilution at 0.5–1 cell/well in 96-well U-bottom microplates in the presence of phytohemagglutinin (0.5 μg/ml), 3 × 10^4 allogeneic γ-irradiated peripheral blood mononuclear cells, and 20 units/ml recombinant interleukin-2 (Roche Applied Science). After 12 days, the growing cells were restimulated with pVIPR-pulsed, γ-irradiat-

---

*This work was financially supported by Deutsche Forschungsgemeinschaft Grant SFB 449, TP B5,B6; Sonnenfeld-Stiftung; COFIN 2001; and Istituto Pasteur Fondazione Cenci-Bolognetti. The costs of publication of this article were defrayed in part by the payment of page charges. This article must therefore be hereby marked “advertisement” in accordance with 18 U.S.C. Section 1734 solely to indicate this fact. The atomic coordinates and structure factors (code 1uxs and 1uxw) have been deposited in the Protein Data Bank, Research Collaboratory for Structural Bioinformatics, Rutgers University, New Brunswick, NJ (http://www.rcsb.org/).

‡‡ To whom correspondence may be addressed. Tel.: 49-30-4505-53953; E-mail: barbara.uchanska-ziegler@charite.de.

‡ These authors contributed equally to this work.

§ These authors contributed equally to this work.

**The abbreviations used are:** AS, ankylosing spondylitis; EBV, Epstein-Barr virus; HLA, human leukocyte antigen; MHC, major histocompatibility complex; HC, heavy chain; CTL, cytotoxic T lymphocyte(s); HIV, human immunodeficiency virus; TCR, T cell receptor.
Refinement

Nonhydrogen atoms

\[
\begin{align*}
R_{\text{cryst}} & = 0.092 (0.179) \\
R_{\text{free}} & = 0.142 (0.202) \\
\text{Estimated overall coordinate error (Å)} & = 0.015 \\
\text{Estimated overall coordinate error based on } R_{\text{free}} & = 0.015
\end{align*}
\]

**METHODS**

**Cytotoxicity Assays**—Cytotoxicity assay of pLMP2-responsive (RRRWRRLTV), pVPIR-responsive (RRKWRWHWL), and pVPIR-pArg2-responsive (RRRWRRLWL) CTL lines and clones was assessed according to the standard 4Cr release procedure (4). Target cells (B*2705 or B*2709 T2 transfectants) were incubated overnight with the pLMP2 or pVPIR peptides at 70 μM or lower concentrations (see “Results” and Fig. 4 for details) in medium alone. One day later, the cells were labeled with sodium chromate and extensively washed before being mixed with effector T cells at 3 x 10^5 target cells/well.

**Analysis of TCR Gene Usage**—Total RNA was extracted from 2 x 10^6 T cells, and cDNA was synthesized using oligo(dT) primer and SuperScript II (Invitrogen) according to the manufacturer’s instructions. For the analysis of TCR α chain usage, cDNA was amplified using primers and PCR conditions as already described (16). Additional oligonucleotides for Vγ families 18–29 were designed as detailed previously (17). PCR products were loaded on a 1.5% agarose gel stained with ethidium bromide. Specific DNA bands were cut from the gel and purified using a gel band purification kit (Amersham Biosciences). Direct sequencing was performed using an internal primer upstream of the TCR Cβ chain usage.

**Protein Preparation and Structure Determination**—The peptide pLMP2 was purified by high pressure liquid chromatography (Alta Bioscience), and HLA-B27-pLMP2 complexes were produced as described (5). Purified complexes (15–20 mg/ml) from 20 mm Tris/HC1, 150 mm NaCl, 0.01% sodium azide, pH 7.5) were used for crystallization using hanging drop vapor diffusion and streak-seeding. Crystals suitable for x-ray diffraction experiments were grown in drops made of 1.5% polyethylene glycol 8000, 0.1 M Tris/HC1, pH 7.5, and for B*2709, 21% polyethylene glycol 8000, 0.1 M Tris/HC1, pH 8.5). Using glycerol as cryoprotectant, data sets were obtained from cryo-cooled (100 K) crystals at the BL2 beam line of BESSY-II. The data were processed with the HKL package (see Table I) (18).

The structure of B*2709-pLMP2 was determined by molecular replacement using peptide-stripped B*2709-m9 (Protein Data Bank code 1kmn) as a search model and the program Molrep (19). After rigid body refinement using Refmac (20), the initial model was subjected to simulated annealing and energy minimization using CNS (21) to remove model bias. Further refinement was carried out by iterative cycles of simulated annealing and restrained maximum-likelihood refinement with Refmac comprising B-factor adjustment. Water molecules were included with ARP/wARP (23). After translation, libration, screw rotation refinement (24), the R factor converged at 0.154 (R_free = 0.190). As the two HLA-B27-pLMP2 complexes crystallized isomorphously, initial phases for B*2709-pLMP2 were calculated from peptide-stripped B*2709-pLMP2 with His116 replaced by alanine. This initial model was subjected to rigid body refinement, simulated annealing, and energy minimization using CNS, improved by manual intervention using O and water molecule inclusion as described for the B*2709-data processing. Because of the higher resolution of B*2705-pLMP2, restrained maximum-likelihood refinement (Refmac) included anisotropic B-factor refinement. Evaluation of the atomic displacement parameters by Parvati (25) provided the expected statistical distribution of 0.5 ± 0.17 for all atoms of the structure. Both structures were validated with WHATCHECK (26), and the statistics are compiled in Table I. The figures were generated using Delphi (27), Povray (www.povray.org), Molscript (28), Rastop (www.geneinfinity.org/rastop), MSMS (29), and Raster3D (30) together with a graphical interface (Moldraw) developed by N. Sträter (Institut für Kristallographie, Freie Universität Berlin). The atomic coordinates and structure amplitudes have been deposited in the Protein Data Bank under accession codes 1uxx (B*2705-pLMP2) and 1uxw (B*2709-pLMP2).

**RESULTS**

**Structural Features of pLMP2 in Complex with HLA-B27 Subtypes**—The B*2705-pLMP2 and B*2709-pLMP2 complexes crystallized isomorphously in space group P2_1 (Table I). Both show the typical MHC class I topography (31) (Fig. 1, a–c) and were refined at high resolution: 1.55 Å for B*2705-pLMP2 and 1.72 Å for B*2709-pLMP2. The HLA-B27 HC and β2-microglobulin are highly similar in the two subtypes (except for the 2-Microglobulin, no. of atoms/average B factor (Å²) 21.0 (4.1) 20.2 (3.7) ; 0.177 (0.202) 0.190 (0.224) ; 0.142 (0.179) 0.154 (0.183) ; 0.015 1.5 ; 0.015 1.6 . When complexed to B*2709, pLMP2 is bound in the conventional p4 (Fig. 1, e) conformation (main chain ϕ/ψ torsion angles in α-helical conformation at p4), with the solvent-exposed pArg2 side chain pointing away from the binding groove (Fig. 1b) (5). In contrast, pLMP2 displays the drastically different p6 (Fig. 1a) conformation (main chain ϕ/ψ torsion angles in α-helical conformation at p6) when bound to B*2709 (Fig. 1a), with the side chain of pArg5 pointing toward the interior of the binding groove, where it forms a salt bridge with HC Asp116 (5). These subtype-dependent pArg orientations force the middle portion (residues p4–p7) of the peptide backbones and the corresponding amino acid side chains into grossly different conformations in the two subtype-specific pLMP2 orientations. The middle portion (residues p4–p7) of the peptide backbones and the corresponding amino acid side chains are grossly different conformations in the two subtype-specific pLMP2 orientations.
subtypes (Fig. 1). Because these regions of the two complexes do not participate in extensive crystal contacts, the observed conformational differences must be a direct consequence of the D116H polymorphism.

The N-terminal pLMP2 residues pArg1, pArg2, and pArg3 occupy identical positions in both subtypes (Fig. 1c and Table II). Both subtypes exhibit also closely related interactions between HC atoms and C-terminal peptide residues pThr8 and pVal9. In B*2709, however, p8 and p9 are located slightly deeper in the binding groove than in B*2705 (Fig. 1, a−c), possibly as a consequence of altered p4−p7 conformations. To account for these changes, the binding groove residues in contact with pThr8 and pVal9 (Table II) exhibit small side chain variations.

pTrp4 is the first pLMP2 residue with substantially different positioning in the two subtypes (Fig. 1, a−e, and Table II). In p4o conformation found in complex with B*2709, the pTrp4, pArg5, and pArg6 side chains are fully solvent-exposed, with few HC contacts, whereas pLeu7 projects into the E-pocket (Fig. 1, b, c, and e, and Table II). A very different situation is found in the p6a conformation seen in B*2705 (Fig. 1, a, c, and d). Here, the pTrp4 side chain is packed against the α1-helix, and pArg6 forms a salt bridge with Asp116 that leads to deeper insertion of the middle section of the peptide into the binding groove (Fig. 1o and Table II). At pArg6, the peptide backbone bends upward (associated with the p6o conformation), so that the side chain can engage in van der Waals’ contact with pTrp4 (Table II). Finally, pLeu7 is solvent-exposed in B*2705, and its side chain exhibits the highest flexibility of all pLMP2 residues in either conformation as shown by temperature (B) factors (Fig. 1, f and g, and Table I). A comparison of the B factors of the peptide reveals that pLMP2 is more flexibly bound in B*2705 despite the anchoring of its middle through the pArg5-Asp116 interaction. This differential peptide flexibility is most likely a consequence of a network of solvent molecules that is tighter in B*2709 than in B*2705, where the hydrophobic section of the pArg6 side chain prevents its formation.

Structural Comparison of pLMP2 and pVIPR in Complexes with B*2705 and B*2709—The four complexes of B*2705 and B*2709 with pLMP2 and pVIPR, respectively, crystallized isomorphously (Ref. 5 and Table I), indicating that the same crystallographic restraints (intermolecular interactions associated with crystal packing) apply to all of them. Comparison of pVIPR complexed with B*2705 and with B*2709 has already been carried out, with the dual p4o/p6a conformation found in B*2705 but not in B*2709, where only p4o occurs (5). Therefore, if molecular mimicry were to play a role in the
context of the pLMP2/pVIPR structures, as suggested by CTL cross-reactivity (4), a comparison of side chain orientations (Fig. 2) and surface properties (Fig. 3) between the two pLMP2 complexes and the two pVIPR complexes should provide a structure-based explanation.

The structures of the two peptides in B*2705 immediately reveal that pLMP2 (Fig. 3a) is much more similar to pVIPR-p6 (Ca root mean square deviation of 0.3 Å; Fig. 3c) than to pVIPR-p4 (Ca root mean square deviation of 1.6 Å; Fig. 3d). pArg1 as well as the anchor residues pArg2 and pVal9/pLeu9 occupy virtually identical positions (Fig. 2, a and b). As expected from the peptide sequences, the similarity of pVIPR and pLMP2 is most pronounced in the N-terminal half, extending to pArg6. In addition to the amino acid exchange at p7, the solvent-exposed pHis8 in pVIPR and pThr8 in pLMP2 lead to a marked topographical change near the peptide C termini (Figs. 2, a and b, and 3, a and c). The similarity between B*2705:pLMP2 (p6α binding mode) and B*2705:pVIPR-p6α extends beyond conformational (Figs. 2, a and b, and 3, a and c) to electrostatic properties of their surfaces (Fig. 3, e and g). As a consequence, pArg3 (pVIPR) also occupies a similar position as pArg3 (pLMP2). However, the side chain guanidinium moieties of both pArg5 residues are solvent-exposed and point to opposite directions (Figs. 2, e and f, and 3, b and d), whereas those in p6α conformation (Figs. 2, a and b, and 3, a, c, e, and g) are buried. pArg6 displays a substantial difference as well; in pLMP2, this side chain is completely solvent-accessible with only a few contacts to the E-helix, whereas it wedges between the peptide backbone and the α1-helix in the complex with pVIPR (5). The Ca atoms of pArgα deviate by 2.3 Å, and the disparity between the guanidinium groups is even larger. Although more similarly positioned, the p7-Ca atoms still differ by 1.6 Å. The side chain of pTrp7 (pVIPR) occupies the front part of the large E-pocket, an impossible location for pLeu7 (pLMP2) because of steric hindrance exerted by the large pArg3 located in the neighboring D-pocket. As a consequence, pLeu7 occupies the back part of the E-pocket, toward the peptide C terminus, is inserted deeper than pTrp7 in pVIPR, and is shifted toward the α1-helix. The peptides deviate only by 1.1 Å at Ca of p8, but the

| Peptide residue | Atom | Contact residue | Distance [Å] | Interaction | Atom | Contact residue | Distance [Å] | Interaction |
|----------------|------|----------------|-------------|------------|------|----------------|-------------|------------|
| pArg1          |      |                |             |            |      |                |             |            |
| pArg2          |      |                |             |            |      |                |             |            |
| pArg3          |      |                |             |            |      |                |             |            |
| pTrp4          | solvent-exposed | pTrp4       | 3.3-3.5    | v.d. Waals |      |                |             |            |
| pArg5          |      |                | 3.5-3.7     | v.d. Waals |      |                |             |            |
| pArg5NH1       |      | Asp116ODIC     | 3.13        | salt bridge|      |                |             |            |
| pArg5NH2       |      | Asp116OD2C     | 2.98        | salt bridge|      |                |             |            |
| pArg6          | solvent-exposed | pArg6GluA   | 3.3-3.5    | v.d. Waals |      |                |             |            |
| pArg6           |      | pTrp4          |             | v.d. Waals |      |                |             |            |
| pLeu7          | solvent-exposed | pLeu7       | ~3.5       | v.d. Waals |      |                |             |            |
| pThr8          |      |                |             | v.d. Waals |      |                |             |            |
| pVal9          |      |                |             | v.d. Waals |      |                |             |            |

a Intrapeptide contact.
b Helix α1.
c β-Sheet floor.
d Helix α2.

TABLE II
Comparison of pLMP2 peptide coordination in the B*2705 and B*2709 subtypes

Only direct intrapeptide contacts and contacts between pLMP2 and HC residues are included, and solvent-mediated interactions are omitted. van der Waals' contacts are not given explicitly for each amino acid. In the B*2705 subtype, pTrp4 and Asp116 occur in alternative conformations. Only one of the equally occupied pTrp4 conformations and the higher occupied Asp116 conformation (q = 0.75) are shown and discussed in the text.

is more likely to occur when pVIPR is displayed in p6α than in p4α conformation.

Surprisingly, the p4α conformations of the two peptides found in B*2709 differ much more (Ca root mean square deviation of 0.9 Å; Figs. 2, e and f, and 3, a, d, and b, and h) than the two p6α conformations in B*2705 (Figs. 2, a and b, and 3, a, e, c, e, and g). Again, residues p1, p2, p4, and p9 show negligible variations, and pLys3 (pVIPR) also occupies a similar position as pArg3 (pLMP2). However, the side chain guanidinium moieties of both pArg5 residues are solvent-exposed and point to opposite directions (Figs. 2, e and f, and 3, b and d, and g, and h). As expected from the peptide sequences, the similarity of pVIPR and pLMP2 is most pronounced in the N-terminal half, extending to pArg6. In addition to the amino acid exchange at p7, the solvent-exposed pHis8 in pVIPR and pThr8 in pLMP2 lead to a marked topographical change near the peptide C termini (Figs. 2, a and b, and 3, a and c). The similarity between B*2705:pLMP2 (p6α binding mode) and B*2705:pVIPR-p6α extends beyond conformational (Figs. 2, a and b, and 3, a and c) to electrostatic properties of their surfaces (Fig. 3, e and g). As expected from the peptide sequences, the similarity of pVIPR and pLMP2 is most pronounced in the N-terminal half, extending to pArg6. In addition to the amino acid exchange at p7, the solvent-exposed pHis8 in pVIPR and pThr8 in pLMP2 lead to a marked topographical change near the peptide C termini (Figs. 2, a and b, and 3, a and c). The similarity between B*2705:pLMP2 (p6α binding mode) and B*2705:pVIPR-p6α extends beyond conformational (Figs. 2, a and b, and 3, a and c) to electrostatic properties of their surfaces (Fig. 3, e and g). As expected from the peptide sequences, the similarity of pVIPR and pLMP2 is most pronounced in the N-terminal half, extending to pArg6. In addition to the amino acid exchange at p7, the solvent-exposed pHis8 in pVIPR and pThr8 in pLMP2 lead to a marked topographical change near the peptide C termini (Figs. 2, a and b, and 3, a and c). The similarity between B*2705:pLMP2 (p6α binding mode) and B*2705:pVIPR-p6α extends beyond conformational (Figs. 2, a and b, and 3, a and c) to electrostatic properties of their surfaces (Fig. 3, e and g). As expected from the peptide sequences, the similarity of pVIPR and pLMP2 is most pronounced in the N-terminal half, extending to pArg6. In addition to the amino acid exchange at p7, the solvent-exposed pHis8 in pVIPR and pThr8 in pLMP2 lead to a marked topographical change near the peptide C termini (Figs. 2, a and b, and 3, a and c).
Fig. 2. Comparison of pVIPR and pLMP2 as presented by B*2705 and B*2709. Superimpositions in two views rotated 90° with respect to each other; selected amino acids are indicated. a and b, superimposition of pLMP2 (yellow) and pVIPR (magenta), both in p6α binding mode, as presented by B*2705 molecules, viewed from the side (a, same view as in Fig. 1a) or the top (b). c and d, superimposition of pLMP2 (yellow, p6α conformation) and pVIPR-p4α (blue) as presented by B*2705 molecules, viewed from the side (c) or the top (d). e and f, superimposition of pLMP2 (green) and pVIPR (blue), both in p4α binding mode, as presented by B*2709 molecules, viewed from the side (e) or the top (f). g, left panel, schematic description of side chain orientations when looking from the N to the C termini of pLMP2, pVIPR-p6α, and pVIPR-p4α in the two HLA-B27 subtypes. The shaded areas indicate structural similarity between the two peptides as presented by B*2705 (dark gray) and B*2709 (light gray). Right panel, floor of peptide binding groove indicated by β-sheet, and binding region for TCR indicated by TCR.

Side chains display different shapes (Fig. 3, b and d) and electrostatic potentials (Fig. 3, f and h). These similarities and differences suggest that pLMP2/pVIPR-cross-reactive CTL from B*2709 individuals are likely to recognize predominantly epitopes formed by p1–p4 (Fig. 2g) and the adjacent residues of the binding groove.

Peptide- and Subtype-dependent CTL Recognition—We have previously shown that autoreactive CTL lines from individuals typing as B*2705 are frequently observed in patients with AS but occur in reduced numbers in healthy individuals. Such CTL are only rarely found in B*2709 individuals, and pLMP2/pVIPR-cross-reactive CTL are infrequently observed among pLMP2-reactive CTL from either subtype (4). To better understand the nature of this cross-reactivity, we have now carried out more extensive studies with CTL, also including CTL clones as well as a hybrid peptide (pVIPR-pArgβ) in which pLysβ (from pVIPR) is replaced by pArgβ (as in pLMP2; Tables III, IV, and V). This exchange was thought to influence epitope recognition by cross-reactive CTL. The ability of pVIPR-pArgβ to stabilize both B*2705 and B*2709 molecules has been evaluated as already described for pVIPR and pLMP2 (Ref. 4 and data not shown).

pLMP2-stimulated CTL from either HLA-B27 subtype detect this peptide also in the context of the other subtype (Table III), implying that structurally similar regions around p1-p3 or p8 provide the epitope(s) (Fig. 1c). About one-sixth of these CTL cross-react with pVIPR at high peptide concentration (70 μM), irrespective of the subtype presenting this peptide. Furthermore, about 25% of the pVIPR-stimulated CTL from B*2705 individuals cross-react with pLMP2 and recognize both peptides also in the B*2709 context. In addition, all pVIPR-stimulated CTL from B*2705 individuals that cross-react with pLMP2 recognize both peptides also in the B*2709 subtype (Table IV). Four pLMP2/pVIPR-cross-reactive CTL lines, two from a B*2709-positive individual (Ci) and two from a B*2705-positive AS patient (MP), were also tested at lower peptide concentrations (Fig. 4). It is evident that when B*2709 presents the two peptides, the dose-response curves have a similar profile (Fig. 4, b, d, f, and h). In contrast, when it is B*2705 that displays the two peptides, the CTL of the patient show a strikingly higher preference for pLMP2 (Fig. 4, e and g), even though they derive from a stimulation with pVIPR. In case of B*2705, the difference between the two peptides was found to be about 100-fold.

The reactivity against pVIPR and pLMP2 either in the B*2705 or in the B*2709 context has been tested also with several clones derived from the CTL line MP VPAC7. Representative dose-response curves of one CTL clone are shown using also lower peptide concentrations (Fig. 4, i and j). The profiles are similar to those obtained with the parental CTL line; in particular, we found that the clonal reactivities were always much stronger against pLMP2, although this peptide was not employed for the initial stimulations of the CTL. TCR gene usage was assessed for 17 clones derived from MP VPAC7. Representative dose-response curves of one CTL clone are shown using also lower peptide concentrations (Fig. 4, i and j). The profiles are similar to those obtained with the parental CTL line; in particular, we found that the clonal reactivities were always much stronger against pLMP2, although this peptide was not employed for the initial stimulations of the CTL. TCR gene usage was assessed for 17 clones derived from MP VPAC7. The results obtained with clone 8 (Fig. 4, i and j) are representative for the others. The same TCR-AY14 chain, CDR3 motif (DRDDKI), and J segment (AJ9S4) were found (Fig. 4k). A higher degree of variability was found for TCR β-chains, but TCRβV1B2S1 chains were predominant among the MP VPAC7-derived clones.

Experiments with the pVIPR-pArgβ peptide show that even a conservative amino acid replacement in the N-terminal half of
the pVIPR peptide (pLys3Arg) 32 can lead to considerable alterations in the reactivity of CTL lines (Table V). pVIPR-pArg abolishes or diminishes the reactivity of the majority of the pVIPR-specific CTL. Lack of reactivity is unlikely to be influenced by the fact that oligoclonal CTL lines were used in the studies reported here, because their oligoclonality would be expected to enhance and not to diminish their cross-reactive potential. Only two CTL (AB4 and AB5) were found that re-

FIG. 3. Molecular surfaces of pLMP2 and pVIPR as presented by B*2705 and B*2709. Molecular surface representations of B*2705 (a, c, e, and g) and B*2709 (b, d, f, and h)complexed with pLMP2 or pVIPR, as viewed by an approaching TCR; color-coding is as in Figs. 1 and 2. a–d demonstrate shape similarities and differences, whereas e–h show the electrostatic surfaces. pVIPR-p4α is presented identically by B*2705 and B*2709 (d and h) (5). Red indicates a negative surface charge, blue indicates a positive surface charge, and gray areas are uncharged.

### Table III

| Donor | Tested on B*2705/pLMP2 | Tested on B*2705/pVIPR | Tested on B*2709/pLMP2 | Tested on B*2709/pVIPR |
|-------|------------------------|------------------------|------------------------|------------------------|
| CV    | 4/4                    | 0/4                    | 0/4                    | 0/4                    |
| MP    | 4/4                    | 2/4                    | 2/4                    | 2/4                    |
| MA    | 3/3                    | 0/3                    | 0/3                    | 0/3                    |
| BO    | 1/1                    | 0/1                    | 0/1                    | 0/1                    |
| EP    | 4/4                    | 0/4                    | 0/4                    | 0/4                    |
| Ci    | 9/9                    | 1/4, 5 NTc             | 2/9                    |                       |

a Donor CV is a healthy HLA-B*2705-positive individual. Donors MP, MA, BO, and EP are HLA-B*2705-positive patients with AS, and donor Ci is an HLA-B*2709-positive healthy individual.

b No. of CTL with positive reactivity/total no. of CTL tested.

c NT, not tested.
tained their level of pVIPR-directed reactivity also with pVIPR-pArg3 (B*2709 not tested), and two others (PM53 and LV1) had reduced activity (B*2702-derived LV1 not tested on B*2709). A single CTL (PM 63) reacted with pVIPR-pArg3 only in the context of B*2709, although pVIPR was recognized when presented by both subtypes.

**DISCUSSION**

The results presented here show that a pathogen-derived peptide such as pLMP2 can exhibit MHC class I subtype-dependent, drastically distinct binding modes (Fig. 1). Although pLMP2 is not an immunodominant peptide for HLA-B*2705 (32), specific CTL are readily detectable in individuals with this subtype (4), and cross-reactivity between B*2705 and B*2709 presenting this peptide is invariably observed (Tables III, IV, and V), most likely because of the existence of nearly identical structures around the N- or C-terminal regions of the complexes (p1–p3 and p8–p9; Figs. 2 and 3 and Table II). Under conditions concerning the behavior in vitro. We have, however, taken great care that the peptides were present during the cytotoxicity tests only in HLA-B27-bound form by washing the target cells before exposure to CTL. This should favor the exclusive presence of the thermodynamically most advantageous conformation, which is very probably that or very close to that observed in the crystals.

Because the peptides exhibit sequence dissimilarity from p7 to p9 (neglecting the conservative exchange pArg3/pLys3) associated with differences in shape and charge distribution (Fig. 3), it seems likely that the N-terminal halves of the peptides give rise to functional and structural mimicry. Remarkably, only one of the two pVIPR conformations (p6e) shows extensive structural mimicry with pLMP2 (Figs. 2 and 3). Here, structural equivalence extends at least from residues p1 to p6 and might even include the area above residue p7. Functional molecular mimicry in B*2705, i.e. CTL cross-reactivity between pLMP2 and pVIPR, could be facilitated also by the higher flexibility exhibited by pLMP2 when bound to this subtype as compared with B*2709 (Fig. 1).

In contrast, cross-reactivity between the conformations of pLMP2 (p6e binding mode) and pVIPR-pArg3 seems much less likely (Figs. 2 and 3). Not only the overall shapes of the two structures are distinct, but the electrostatic surfaces exhibit considerable dissimilarity as well. Only the surfaces around
Comparison of the lytic potential of pLMP2/pVIPR-cross-reactive CTL. Dose-response curves (effector:target ratio, 15:1) show the cytotoxic activity of four pLMP2-stimulated (a–d) or pVIPR-stimulated (e–h) CTL lines against T2-B*2705 (a, c, e, and g) or T2-B*2709 (b, d, f, and h) cells pulsed with pLMP2 or pVIPR at different concentrations. i and j show the dose-response curves of the cytotoxic activity (effector:target ratio, 3:1) of a representative clone (clone 8) derived from the CTL line MP VPAC 7. The spontaneous release of ¹⁵⁵Cr-labeled cells was less than 15%. One of three separate experiments is shown. The sequence of the TCRα-chain expressed by clone 8 (k, upper line, in bold) as well as that of cross-reactive clones (k, lower line, in italics) with specificity for peptides derived from the BZLF1 protein of EBV and a serine/threonine kinase (see text) (34) are also depicted.
the residues p1–p3 are very similar. The reactivities of pVIPR-specific CTL with pVIPR- or pVIPR-pArg*-loaded B*2705 molecules corroborate these conclusions (Tables III, IV, and V). They show that the majority of CTL is negatively influenced by the plys Arg replacement, suggesting that the epitopes of their TCR encompass the area around this residue. TCR α-chain-binding footprints are generally located above the N-terminal half of the peptides and the surrounding binding groove residues (42–46). Therefore, an involvement of the N-terminal half of the pLM2 peptide and pVIPR peptides as putative TCR epitopes suggests that TCR α-chains may contribute to the recognition process.

This assumption is supported by our finding that CTL clones derived from the MP VPAC 7 line use the same TCR α-chain CDR3 and J-region motifs as clones shown to recognize two peptides derived from a viral (BZLF1 protein of EBV, RAK-FKQLL) and a self-protein (serine/threonine kinase, RSKFRR-QIV) (34) (Fig. 4). These otherwise completely unrelated CTL clones (HLA-B27- or HLA-B8-restricted, respectively) each recognize peptides with pArg1. It appears therefore plausible that charge complementarity between pArg and aspartic acid residues in the TCR α-chain CDR3 regions of both types of CTL could be crucial to the recognition process, supporting our assumption of the particular relevance of the N-terminal half of the peptides in pLM2/pVIPR functional and structural mimicry. However, it is currently unknown whether a relationship exists between the observed cross-reactivity of the two HLA-B27-presented peptides, the development of differential T cell repertoires in the two subtypes, and AS pathogenesis. It even remains possible that pLM2 and pVIPR are not the peptides that exhibit molecular mimicry relevant in the context of AS but other, possibly heteroclitic, peptides that exhibit cross-reactivity with the former. Nevertheless, these two peptides allow elucidation of the structural basis of TCR cross-reactivity in HLA-B27 subtypes that are differentially associated with an autoimmune disease (1–4).

MHC class II molecules are more likely to generate examples of structural mimicry of T cell epitopes than class I antigens (8, 9), because peptides are anchored not only at the termini but also at several positions along an MHC class II binding groove. This allows the formation of highly similar TCR epitopes even when distantly related peptides are presented by different HLA class II molecules (9). However, functional molecular mimicry has already been shown for MHC class I antigens in mice and humans, and EBV-specific memory T cell clones recognizing cross-reactive self-peptides have been found in the periphery (34) and even in joints (47). Our results complement functional data (4, 5, 34, 47) by providing a structural basis for CTL cross-reactivity also for class I molecules, with the pLM2 and pVIPR peptides presented by HLA-B27 antigens as paradigms. These results suggest that cellular mechanisms underlying disease association with HLA class I antigens may be fundamentally different from those observed with HLA class II molecules.

The four criteria required for a clear-cut case of molecular mimicry as a cause for autoimmunity (48) are only partially fulfilled in the context of HLA-B27. There is evidence for T cells directed against a self-antigen (pVIPR) nearly exclusively in individuals with the AS-associated subtype (4), and a viral mimic (pLM2) of this self-antigen has been identified (Ref. 4 and this study). On the other hand, although the presence of EBV-specific and self-cross-reactive CTL has been demonstrated in the periphery and joints, for example in patients with oligoarticular juvenile idiopathic arthritis (49), an epidemiological association between AS and EBV has not been found so far and is hard to demonstrate given the fact that about 90% of humans get this infection during the first decades of life (35). Furthermore, no animal models are available involving presentation of pVIPR and pLM2 in the context of HLA-B27. It is currently unknown whether the structural mimicry described here and the functional dichotomy between B*2705 and B*2709 extend to HLA-B27 subtypes such as B*2704 and B*2706, which are differentially associated with AS as well (1).

Our findings might be relevant not only in the context of autoimmune diseases but are likely to influence also our understanding of conditions leading to acceptance or rejection of transplants (50), in particular bone marrow grafts from unrelated donors (51). In addition, polymorphism of HC residue 116 has already been shown to exert an influence on the progression to AIDS among HIV-1+ patients with different HLA-B35 subtypes; alleles with a Ser116 (B*3501 and B*3508) were associated with slow progression, whereas B*3503 (Phe116 but otherwise identical to B*3501) was associated with more rapid progression (52). This difference has been suggested to be due to differential binding of HIV-derived peptides by these subtypes (52).

Structural data comparing the B*3501/B*3503 pair are not available, but a direct effect of residue 116 polymorphism on the repertoire of bound peptides through interaction with the C-terminal peptide side chain (3, 53, 54) or even with an amino acid within the middle of a peptide such as pVIPR (5) or pLM2 (this study) has been demonstrated. Furthermore, the peptide repertoire may also be influenced indirectly by residue 116 polymorphism. This may be achieved through differential dependence on the chaperone tapasin for loading of peptide cargo (54–59). For example, B*4405 can be relatively efficiently loaded with peptides also in the absence of tapasin, whereas B*4402 (differing from B*4405 only in residue 116) exhibits a complete dependence on this chaperone (54). The surface expression of tapasin-dependent HLA class I alleles may be drastically impaired, with obvious consequences for the immune response, when tapasin function is inhibited, as by the viral US3 protein following an infection with cytomegalovirus (59). Although as yet unproven, it remains a distinct possibility that B*2705 and B*2709 also exhibit differential tapasin dependence (60). In conclusion, residue 116-dependent differential peptide presentation and the ensuing distinct CTL responses could well serve to explain several of the HLA class I subtype-dependent immune phenomena observed in AS as well as in the other disease states mentioned above.

Acknowledgments—We thank all patients and healthy probands for participation in this study and are grateful to Dr. U. Müller for help with x-ray data collection at BESSY II.

REFERENCES

1. Ramos, M., and López de Castro, J. A. (2002) Tissue Antigens 60, 191–205
2. D’Amato, M., Fiorillo, M. T., Carcassi, C., Mathieu, A., Zucchiarelli, A., Bitti, P. P., Toni, S., and Sorrentino, R. (1995) Eur. J. Immunol. 25, 3199–3201
3. Ramos, M., Paradela, A., vanoz, M. A., Marina, A., Vanque, J., and López de Castro, J. A. (2002) J. Biol. Chem. 277, 32749–32756
4. Fiorillo, M. T., Maragno, M., Butler, R., Dupuis, M. L., and Sorrentino, R. (2000) J. Clin. Invest. 106, 47–53
5. Hulsmeyer, M., Fiorillo, M. T., Bettostini, F., Sorrentino, R., Saenger, W., Ziegler, A., and Uehacska-Ziegler, B. (2004) J. Exp. Med. 199, 271–281
6. Oldstone, M. B. (1987) Cell 50, 819–820
7. Benjamin, R., and Parham, P. (1990) Immunol. Today 11, 137–142
8. Wucherpfennig, K. W. (2001) J. Autoimmun. 16, 293–302
9. Lang, H. L., Jacobsen, H., Ikenizu, S., Andersson, C., Harlos, K., Madsen, L., Hjorth, P., Sondergaard, L., Svejgaard, A., Wucherpfennig, K., Stuart, D. I., Bell, J. J., Jones, E. Y., and Fugger, L. (2002) Nat. Immunol. 3, 940–943
10. Gecy, A. F., and Yap, J. (1982) J. Immunol. 128, 271–281
11. Schwimmbeck, P. L., Yu, D. T., and Oldstone, M. B. (1987) J. Exp. Med. 166, 173–181
12. Ramos, M., Alvarez, I., Sesma, L., Logean, A., Rognan, D., and López de Castro, J. A. (2002) J. Biol. Chem. 277, 37573–37581
13. Tiwana, H., Walshe, R. S., Wilson, C., Taniakou, J. Y., Colièra, P. J., Wakefield, A. J., and Ehringer, A. (1998) Br. J. Rheumatol. 37, 925–931
14. Stone, M. A., Payne, U., Schentag, C., Rahmann, P., Pacheco-Tena, C., and Inman, R. D. (2004) Rheumatology 43, 148–155
15. Wucherpfennig, K. W., and Strominger, J. L. (1995) Cell 80, 695–705
Allele-dependent Similarity between Viral and Self-peptide Presentation by HLA-B27 Subtypes
Maria Teresa Fiorillo, Christine Rückert, Martin Hülsmeyer, Rosa Sorrentino, Wolfram Saenger, Andreas Ziegler and Barbara Uchanska-Ziegler

J. Biol. Chem. 2005, 280:2962-2971.
doi: 10.1074/jbc.M410807200 originally published online November 10, 2004

Access the most updated version of this article at doi: 10.1074/jbc.M410807200

Alerts:
- When this article is cited
- When a correction for this article is posted

Click here to choose from all of JBC's e-mail alerts

This article cites 58 references, 15 of which can be accessed free at http://www.jbc.org/content/280/4/2962.full.html#ref-list-1